ALXO

STRUCTURAL ANALYST NOTE: ALXO (ALX Oncology Holdings Inc.)

Date: 2026-06-12 Current Price: $2.15

1. Structural Readiness

• State: FORMING
• Conservative Entry: Not yet actionable. Requires a confirmed close above the resistance level defined by the coil's upper boundary (breakout level).
• Aggressive/Pre-Breakout Entry: $2.15 (Current Price). This represents a "partial" setup readiness signal.
• Breakout Level: Not yet defined (requires price to close above the recent consolidation high).
• Extension: N/A (Price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 9.7% (Extreme). This indicates severe volatility and high risk of whipsaw. Historically, extreme ATR readings correlate with a higher probability of structural failure if the setup is invalidated, but also higher potential reward if the breakout succeeds.

2. Thesis Layer

• Primary Secular Thesis: biotech_platform_breakthroughs
• Role & Directness: ALXO is a direct beneficiary of the "next-generation checkpoint inhibitor" thesis. The company is developing evorpacept (ALX148), a CD47 blocker designed to overcome the hematologic toxicities that have plagued previous generations of CD47 inhibitors.
• Thesis Weighting: The thesis is reinforced by the EGFR-targeted ADC pipeline (ALX2004), which leverages the clinically validated EGFR target. While the primary driver is the CD47 platform breakthrough, the dual-pipeline approach (CD47 + EGFR-ADC) provides a secondary layer of secular exposure to immuno-oncology and antibody-drug conjugate innovation. The company's collaboration with Tallac Therapeutics further validates the platform's potential to engage both innate and adaptive immune systems.

3. Business Analysis

• Company Overview: ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology firm focused on developing innovative therapies for cancer patients.
• Business Model: The company operates on a "platform" model, developing proprietary small molecule and antibody-based therapeutics. Revenue is currently non-existent; the business model relies on capital raising to fund clinical trials, with the ultimate goal of licensing, partnering, or commercializing approved assets.
• Industry: Biotechnology / Immuno-Oncology.
• Supporting Evidence (as of 2026-06-12):
• Pipeline Status: The company has two clinical-stage candidates: evorpacept (CD47 blocker) and ALX2004 (EGFR-targeted ADC).
• Clinical Progress (Evorpacept):
• In January 2026, the company announced the first patient had been dosed in a Phase 2 trial for HER2-positive metastatic breast cancer (E6).
• In March 2025, the intent to initiate this Phase 2 trial was announced (E1).
• In April 2025, the FDA provided guidance that the ASPEN-06 Phase 2 trial data for "Evo-TRP" was not eligible for accelerated approval due to the availability of ENHERTU, prompting a strategic pivot to the HER2-positive breast cancer combination trial (E12).
• Approximately 800 subjects have been treated with evorpacept in combination with other agents to date (E11).
• Clinical Progress (ALX2004):
• In August 2025, the first patient was dosed in the first-in-human Phase 1 trial for advanced solid tumors (E7).
• In January 2026, the trial began enrolling patients in the third dose cohort at 4 mg/kg after successfully clearing the second dose cohort (E8).
• Financial Runway: Management stated in the March 2026 filing that existing capital resources are sufficient to fund projected operating requirements for at least the next twelve months (E3).
• Strategic Collaborations:
• Collaboration with Tallac Therapeutics for novel immunotherapeutics (E15).
• Phase 2 trial with Merck evaluating ALX148 with pembrolizumab for head and neck cancer (E19).
• Partnership with Zymeworks for a Phase 1 trial assessing ALX148 with zanidatamab (E20).

4. Archetype and Conviction

• Archetype: Growth Leader (Pre-Revenue / Clinical Catalyst)
• *Note:* While "Growth Leader" typically implies revenue, in the biotech context, this archetype applies to companies with validated platforms and active clinical pipelines that are not yet commercialized. The company is not a "deep value recovery" or "cyclical recovery" play; it is a binary clinical-stage asset.
• Valuation Context: No financial spine (revenue/profit) is available for traditional valuation multiples. Valuation is driven entirely by the probability of clinical success and the remaining cash runway.
• Conviction Stack:
• Thesis Strength: High. The CD47 mechanism is a validated secular theme, and ALXO's specific approach (high affinity, reduced toxicity) addresses a known market failure.
• Evidence Quality: Strong. Multiple Phase 1/2 trials are active, with specific dosing milestones met in 2025 and 2026.
• Structural Quality: Moderate. The setup is "Forming," meaning the technical structure is present but unconfirmed. The Extreme ATR (9.7%) is a significant negative factor, suggesting high volatility and potential for false breakouts or rapid invalidation.
• Rerating Potential: High, contingent on positive Phase 2 data or successful Phase 1 dose escalation for ALX2004.
• ATR Analysis: The current ATR of 9.7% is in the "Extreme" bucket (>8%). Historically, this is the highest historical severe-loser rate bucket. This suggests that while the setup is forming, the risk of a sharp, violent move against the position is elevated. Position sizing must be conservative relative to the setup's potential.

5. Invalidation, Strengthening, and Gaps

• Invalidation Triggers:
• Negative clinical data from the ongoing Phase 2 (evorpacept) or Phase 1 (ALX2004) trials.
• A cash runway extension warning (e.g., management stating capital is insufficient for the next 12 months).
• Strengthening Triggers:
• A confirmed close above the consolidation high (breakout).
• Positive interim data readouts from the HER2-positive breast cancer trial or the ALX2004 dose escalation.
• Announcement of a new strategic partnership or licensing deal.
• Evidence Gaps:
• Specific Financials: No specific cash balance or burn rate figures are provided in the evidence block, only the management expectation of a 12-month runway.
• Detailed Toxicity Data: While the thesis mentions avoiding hematologic toxicities, specific quantitative safety data from the 800 treated subjects is not detailed in the provided evidence.
• Market Size: No specific TAM (Total Addressable Market) figures for the specific indications (HER2+ breast cancer, EGFR solid tumors) are provided.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Two active clinical-stage candidates (evorpacept and ALX2004) with recent dosing milestones in 2025-2026; management guidance of 12-month capital runway; strategic partnerships with Merck and Zymeworks. Key risks: Extreme ATR volatility (9.7%) increases risk of structural failure; binary clinical trial outcomes; FDA guidance previously rejected accelerated approval for a related indication; no revenue generation. Sizing hint: Small position size due to extreme volatility and binary nature of clinical catalysts; treat as a partial setup readiness signal rather than a confirmed breakout. Expected path: Price consolidates near current levels while clinical data matures; potential for a breakout if positive data is released or if the structure holds through the 12-month runway period. Expected horizon: 6 to 18 months (aligned with clinical trial milestones and cash runway). Failure mode to watch: A daily close below $2.15, which would invalidate the forming coil structure and signal a loss of structural support.